menveo
glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solution for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.
nimenrix
pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - powder and solvent for solution for injection - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.
nimenrix powder and solvent for solution for injection
pfizer private limited - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w-135 polysaccharide; neisseria meningitidis group y polysaccharide; tetanus toxoid carrier protein - injection, powder, for solution - 5 micrograms - neisseria meningitidis group a polysaccharide 5 micrograms; neisseria meningitidis group c polysaccharide 5 micrograms; neisseria meningitidis group w-135 polysaccharide 5 micrograms; neisseria meningitidis group y polysaccharide 5 micrograms; tetanus toxoid carrier protein ~44 micrograms
menveo powder and solution for solution for injection
glaxosmithkline pte ltd - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein - injection, powder, for solution - 10 microgram conjugated to 16.7-33.3 microgram - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein 10 microgram conjugated to 16.7-33.3 microgram; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein 5 microgram conjudated to 7.1-12.5 microgram; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 3.3-8.3 microgram; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 5.6-10 microgram
menactra® solution for injection
sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.
neisvac-c 0.5 ml suspension for injection in pre-filled syringe. meningococcal group c polysaccharide conjugate vaccine adsorbed
pfizer healthcare ireland - neisseria meningitidis c; tetanus toxoid - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - meningococcal vaccines - meningococcal vaccine - it is indicated for active immunisation in children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.
neisvac-c, 0.5 ml. suspension for injection in pre-filled syringe. meningococcal group c polysaccharide conjugate vaccine adsorbed
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - neisseria meningitidis, polysaccharide group, tetanus toxoid - suspension for injection - neisseria meningitidis polysaccharide group c tetanus toxoid - vaccines
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen
nimenrix
pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135, and y.